Dong-A ST Co., Ltd. (KRX:170900)

Market Cap	388.34B -5.8%
Revenue (ttm)	808.78B +15.9%
Net Income	-28.59B
EPS	-2,970.54
Shares Out	9.61M
PE Ratio	n/a
Forward PE	15.95
Dividend	666.67 (1.60%)
Ex-Dividend Date	Mar 10, 2026

Volume	10,431
Average Volume	19,937
Open	40,400
Previous Close	40,400
Day's Range	40,400 - 41,150
52-Week Range	40,250 - 56,381
Beta	0.46
RSI	33.48
Earnings Date	Apr 27, 2026

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Closerin for active pulmonary and extra-pulmonary tuberculosis; Dulastin and Leucostim for neutropenia in patients receiving myelosuppressive chemotherapy; Eporon for anemia associated with chronic renal failure; Gemcit for non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin for infertility and annovulation; Growtropin II for growth failure due to an inadequate sec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 170900

Financial Performance

In 2025, Dong-A ST's revenue was 808.78 billion, an increase of 15.89% compared to the previous year's 697.87 billion. Losses were -28.59 billion, 2237.8% more than in 2024.